First-in-Class Vepdegestrant Approved in Advanced Breast Cancer
Summary
Oral agent in second-line more than doubled median PFS in patients with <em>ESR1</em> mutations
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.